Ulrich Mrowietz

University Hospital Schleswig-Holstein — Germany

Immunology and Microbiology · Life Sciences

81h-index25.2kcitations577works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(323), Dermatology and Skin Diseases(229), Autoimmune Bullous Skin Diseases(78), Asthma and respiratory diseases(56), Health Systems, Economic Evaluations, Quality of Life(41)

Publications576 total

Perianal, whitish, hard papules in an infant
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025
62989 Improvements in Quality of Life With Apremilast Treatment in Patients With Plaque Psoriasis With Two or Three High-impact sites Affected: Post-hoc Analysis of the EMBRACE Trial
Journal of the American Academy of Dermatology·2025
63300 Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT
Journal of the American Academy of Dermatology·2025
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
Dermatology and Therapy·2025· 1 citedOpen Access
Nicotinuric acid acts as a pro-diabetic tryptophan metabolite in human and rodent obesity
Diabetologie und Stoffwechsel·2025
Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study
American Journal of Clinical Dermatology·2025· 2 citedOpen Access
German Smile
Deutsche Dermatologie·2025
Indikation zur Systemtherapie bei Psoriasis: Kommentierte Checkliste für die Praxis
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis
Journal of Investigative Dermatology·2025· 5 citedOpen Access
PCR110 Improving Patients’ Well-Being and Psoriasis-Related Work Productivity With Tildrakizumab: 52-Week Interim Results From the Phase IV Real-World Positive Study in Patients With Moderate-to-Severe Plaque Psoriasis
Value in Health·2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Dermatology and Therapy·2024· 10 citedOpen Access
Efficacité du tildrakizumab sur les démangeaisons, la douleur et la fatigue chez les patients atteints de psoriasis modéré à sévère : résultats à 52 semaines de l’étude POSITIVE en situation de vie réelle
Annales de Dermatologie et de Vénéréologie - FMC·2024
Efficacité et sécurité du tildrakizumab chez les patients atteints de psoriasis modéré à sévère avec des localisations spécifiques : résultats à 52 semaines de l’étude de phase IV POSITIVE
Annales de Dermatologie et de Vénéréologie - FMC·2024
Les patients atteints de psoriasis modéré à sévère traités par tildrakizumab rapportent un indice de bien-être équivalent à celui de la population générale sans maladie chronique
Annales de Dermatologie et de Vénéréologie - FMC·2024
52653 Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study
Journal of the American Academy of Dermatology·2024Open Access
51186 Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase IV POSITIVE study
Journal of the American Academy of Dermatology·2024Open Access
Psoriasis as a systemic disease
Deutsches Ärzteblatt international·2024· 33 citedOpen Access
SARS‐CoV‐2‐Infektionen bei Patienten mit Psoriasis in Deutschland: Daten aus den deutschen Registern PsoBest und CoronaBest
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2024Open Access
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest
Journal of Clinical Medicine·2024· 2 citedOpen Access
SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2024Open Access
page 1 of 29Next →

Frequent Co-authors

Kristian Reich(11), Catherine Smith(10), Juliet N. Barker(8), Alexander Nast(8), Eva Ellinghaus(7), Stephan Weidinger(7), Michael Weichenthal(7), André Franke(7), James T. Elder(7), Philip E. Stuart(6), Rajan P. Nair(6), Paolo Gisondi(6), Trilokraj Tejasvi(5), Sulev Kõks(5), Külli Kingo(5), John J. Voorhees(5), Proton Rahman(5), Dafna D. Gladman(5), Gonçalo R. Abecasis(5), Phyllis I. Spuls(5)